Good morning, everyone, and welcome to another working week. We hope the long holiday respite was refreshing and enjoyable, because that familiar routine of meetings, deadlines, and whatnot has now returned. You knew this would happen, yes? To cope, we are relying on a few cups of needed stimulation — our flavor today is Rain Forest Nut — and you are, of course, invited to join us. Meanwhile, here is the latest menu of tidbits. Quite a few, since we are playing catch-up this morning. Have a smashing day and do stay in touch …
Roche dropped out of a high-profile project to develop an antibiotic for treating superbugs and returned the compound to Polyphor, its development partner, Reuters writes. Two years ago, Roche agreed to pay Polyphor up to $485.3 million for rights to the product. The deal generated notice at the time because it was a rare for a major drug maker to enter the battle against superbug infections in hospitals.
Neil Woodford, a UK fund manager and a major shareholder in Northwest Biotherapeutics, is urging the biotech firm to probe allegations about governance issues involving Linda Powers, the chairman and chief executive, The Wall Street Journal says. She denied financial irregularities between Northwest and entities related to her, and maintained that payments for services had been cleared by the Northwest board, independently audited, and filed with regulators.
About the Author Reprints
